Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into a strategic relationship with healthcare company AmerisourceBergen in preparation for the anticipated commercial launch in the United States of its ONS-5010 treatment for wet age-related macular degeneration (AMD).
ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.
Outlook Therapeutics said under the commercialization agreement AmerisourceBergen would provide third-party logistics services and distribution, as well as medical information and pharmacovigilance services in the US.
READ: Outlook Therapeutics re-submits biologics license application for ONS-5010 as a treatment for wet AMD to the FDA
The company said as it moves toward a potential launch of ONS-5010 in the United States pending approval by the US Food and Drug Administration (FDA), AmerisourceBergen’s commercialization support would expand to include additional services, such as patient services and field solutions.
Outlook Therapeutics CEO C Russell Trenary III said entering a relationship with AmerisourceBergen for ONS-5010 was a critical step in the next phase of its pre-commercial strategy execution.
“AmerisourceBergen is the preeminent leader in specialty pharma distribution, which will provide expansive reach and access to the vast majority of anti-VEGF providers,” he said.
“This is expected to significantly enhance our commercial reach. Together, we believe we will be in a position to significantly upgrade treatment options for people living with wet AMD.”
AmerisourceBergen's president of global pharma services Willis Chandler added: “We are thrilled to support Outlook Therapeutics for their pre-commercial launch preparations and, pending FDA approval, plan to leverage our portfolio of commercialization solutions to help them maximize commercial success and increase patient access.”
Outlook Therapeutics said it is also exploring a relationship with AmerisourceBergen to support the launch of ONS-5010 in international markets.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie